[{"id":"e0140ec6-c75d-43bd-8e7c-53aed0cb1b56","acronym":"WIN-B","url":"https://clinicaltrials.gov/study/NCT06612203","created_at":"2025-02-25T18:45:57.055Z","updated_at":"2025-02-25T18:45:57.055Z","phase":"Phase 1/2","brief_title":"Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer","source_id_and_acronym":"NCT06612203 - WIN-B","lead_sponsor":"MedSIR","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy) • zedoresertib (Debio 0123)"],"overall_status":"Recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 01/17/2025","start_date":" 01/17/2025","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-01-24"}]